News coverage about Synlogic (NASDAQ:SYBX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synlogic earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.6925724845952 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Q1 2018 Earnings Forecast for Synlogic Inc (SYBX) Issued By Wedbush (americanbankingnews.com)
- Synlogic Inc (SYBX) Expected to Earn FY2022 Earnings of ($1.17) Per Share (americanbankingnews.com)
- Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic Disorders (finance.yahoo.com)
- Contrasting Synlogic (SYBX) and Auxilium Pharmaceuticals (AUXL) (americanbankingnews.com)
- $110,000.00 in Sales Expected for Synlogic Inc (SYBX) This Quarter (americanbankingnews.com)
Several research analysts have recently commented on the company. Zacks Investment Research upgraded Synlogic from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Wedbush started coverage on Synlogic in a research report on Monday, November 27th. They set an “outperform” rating and a $20.00 price objective for the company. ValuEngine downgraded Synlogic from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Piper Jaffray Companies initiated coverage on Synlogic in a research report on Monday, January 29th. They set an “overweight” rating and a $16.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Synlogic presently has an average rating of “Hold” and an average target price of $18.75.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/17/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-synlogic-sybx-stock-price/1901661.html.
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.